Category: Pα+ - Psychedelic Alpha

Read more about the article Pα+ Psychedelic Bulletin #201: Dispatches from Prague and London; Texas Becomes Leader in Ibogaine Research as Governor Signs $50M Match-Funding Bill; High-Dose LSD Shows Potential in Depression, But Findings Are Fragile

Pα+ Psychedelic Bulletin #201: Dispatches from Prague and London; Texas Becomes Leader in Ibogaine Research as Governor Signs $50M Match-Funding Bill; High-Dose LSD Shows Potential in Depression, But Findings Are Fragile

Post published:June 13, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article May 2025 Psychedelic Patent Update: Gilgamesh Broadens Moat Around Lead Candidate Following Positive Phase 2a Readout; Lykos Publishes Further Continuation Applications; Reconnect Joins Crowded 5-MeO-DMT Patent Landscape

May 2025 Psychedelic Patent Update: Gilgamesh Broadens Moat Around Lead Candidate Following Positive Phase 2a Readout; Lykos Publishes Further Continuation Applications; Reconnect Joins Crowded 5-MeO-DMT Patent Landscape

Post published:June 12, 2025
Post category:Psychedelic Patent Analysis Pα+

Read more about the article Breaking: atai Moves to Acquire Beckley, If Phase 2b 5-MeO-DMT Data Delivers

Breaking: atai Moves to Acquire Beckley, If Phase 2b 5-MeO-DMT Data Delivers

Post published:June 2, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #199: Lykos Takeover Nears Completion; Fewer than 100 Patients Received Psychedelics in Australia During First 18 Months of Access; Ibogaine Bill Clears Texas Legislature Amid THC Crackdown

Pα+ Psychedelic Bulletin #199: Lykos Takeover Nears Completion; Fewer than 100 Patients Received Psychedelics in Australia During First 18 Months of Access; Ibogaine Bill Clears Texas Legislature Amid THC Crackdown

Post published:May 30, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Gilgamesh’s Next-Gen Psychedelic GM-2505 Prints Impressive Results in Phase 2a Major Depressive Disorder Study

Gilgamesh’s Next-Gen Psychedelic GM-2505 Prints Impressive Results in Phase 2a Major Depressive Disorder Study

Post published:May 27, 2025
Post category:Analysis News Pα+

Read more about the article Matt Zorn, the Government’s Former Adversary, Is Now Its Psychedelics Czar

Matt Zorn, the Government’s Former Adversary, Is Now Its Psychedelics Czar

Post published:May 24, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #198: New Data Offers Look at Spravato’s Long-Term Use, Highlights Psychedelic Opportunity; MAHA Report Slams Psychiatric Meds; Momentum Builds for Beckley

Pα+ Psychedelic Bulletin #198: New Data Offers Look at Spravato’s Long-Term Use, Highlights Psychedelic Opportunity; MAHA Report Slams Psychiatric Meds; Momentum Builds for Beckley

Post published:May 23, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article FDA’s Makary Hints at Faster Reviews for Psychedelic Therapies

FDA’s Makary Hints at Faster Reviews for Psychedelic Therapies

Post published:May 19, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #197: Portuguese Health-Related Professions Unite on Psychedelics; Shrooms, Shots, and the Next Surgeon General; Religious Leaders Study Set to Publish

Pα+ Psychedelic Bulletin #197: Portuguese Health-Related Professions Unite on Psychedelics; Shrooms, Shots, and the Next Surgeon General; Religious Leaders Study Set to Publish

Post published:May 16, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Spring 2025 Psychedelic Policy Update: Bills Hang in the Balance as Legislative Sessions Wind Down

Spring 2025 Psychedelic Policy Update: Bills Hang in the Balance as Legislative Sessions Wind Down

Post published:May 13, 2025
Post category:Analysis News Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.